Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Promising combo targets tough leukemia in early trial

NCT ID NCT03504644

Disease control Sponsor: ECOG-ACRIN Cancer Research Group Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Aug 07, 2026 · Updated 2 times

Summary

This study tests a combination of two drugs—venetoclax and vincristine—in people with T-cell or B-cell acute lymphoblastic leukemia that has returned or not responded to prior treatment. The goal is to find the safest dose and see if the combo can lead to remission. About 40 adults will take part in this early-phase trial.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1/2

Runs two stages together: safety and dose first, then whether the treatment works.

Participants

40 people

The number who actually took part.

Started

Aug 2018

Expected to finish

Dec 2028

An estimate. End dates often move.

Lead sponsor

A research network

The lead sponsor is a research network or cooperative group.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * ELIGIBILITY CRITERIA - PHASE I (ARMS A, B, C) - STEP 0: Patient must be considered a potential candidate for the trial * NOTE: Enrollment to Step 0 may occur prior to or following completion of the assessments to verify patient eligibility for Step 1 registration; bone marrow and/or peripheral blood specimens collected during Step 0 or prior to treatment on Step 1 must be submitted for central review in order for the patient to be considered evaluable; results will not be reported to the site and will not impact patient participation in the trial * ELIGIBILITY CRITERIA - PHASE I (ARMS A, B, C) - STEP 1: Patients must have a diagnosis of: * Relapsed or refractory B-cell or T-cell ALL after multi-agent chemotherapy * Patients with \< 5% blasts may enroll on trial in phase I portion provided that minimal residual disease (MRD) is present at \> 10\^-3 as tested on an assay with minimum sensitivity of 10\^-4 OR * Relapsed lymphoblastic lymphoma * ELIGIBILITY CRITERIA - PHASE I (ARMS A, B, C): Age \>= 18 years * ELIGIBILITY CRITERIA - PHASE I (ARMS A, B, C) - STEP 1: Eastern Cooperative Oncology Group (ECOG) performance status 0-2 * ELIGIBILITY CRITERIA - PHASE I (ARMS A, B, C) - STEP 1: Adequate liver function with aspartate aminotransferase (AST)/alanine aminotransferase (ALT) less than 3 x upper limit of normal and total bilirubin less than 2 mg/dL within 10 days prior to first dose of study agent * ELIGIBILITY CRITERIA - PHASE I (ARMS A, B, C) - STEP 1: Circulating white blood cell (WBC) count must not be above 25 x 10\^9/L at the time of registration * Patients with WBC count above 25 x 10\^9/L are eligible if they have started steroids or hydroxyurea per institutional guidelines * ELIGIBILITY CRITERIA - PHASE I (ARMS A, B, C) - STEP 1: Glomerular filtration rate (GFR) of at least 40 mL/min within 7 days prior to first dose of study agent * ELIGIBILITY CRITERIA - PHASE I (ARMS A, B, C) - STEP 1: All patients of childbearing potential must have a blood test or urine study with a minimum sensitivity 25 IU/L or equivalent units of human chorionic gonadotropin (HCG) within 2 weeks prior to registration to rule out pregnancy * A patient of childbearing potential is defined as anyone, regardless of sexual orientation or whether they have undergone tubal ligation, who meets the following criteria: 1) has achieved menarche at some point, 2) has not undergone a hysterectomy or bilateral oophorectomy; or 3) has not been naturally postmenopausal for at least 24 consecutive months (i.e., has had menses at any time in the preceding 24 consecutive months) * ELIGIBILITY CRITERIA - PHASE I (ARMS A, B, C) - STEP 1: Patients must not expect to conceive or father children by using accepted and highly effective method(s) of contraception or by abstaining from sexual intercourse for the duration of their participation in the study and for 30 days after the last dose of venetoclax * Should a patient or a partner of a patient become pregnant or suspect they are pregnant while participating in the study, the treating physician should be notified immediately * ELIGIBILITY CRITERIA - PHASE I (ARMS A, B, C) - STEP 1: No evidence of prior solid malignancy except adequately treated non-melanoma skin cancer, in situ cervical carcinoma, or any surgically- or radiation-cured malignancy continuously disease free for \>= 2 years so as not to interfere with interpretation of radiographic response * ELIGIBILITY CRITERIA - PHASE I (ARMS A, B, C) - STEP 1: Patients may be enrolled with a prior allogeneic hematopoietic stem cell transplant (HSCT) but the transplant date must be at least 90 days before date of registration to step 1; patient must be off immunosuppression and without active graft versus host disease (GVHD) prior to registration to step 1 if previous HSCT * ELIGIBILITY CRITERIA - PHASE II (ARM D) - STEP 0: Patient must be considered a potential candidate for the trial * NOTE: Enrollment to Step 0 may occur prior to or following completion of the assessments to verify patient eligibility for Step 1 registration * ELIGIBILITY CRITERIA - PHASE II (ARM D) - STEP 1: Relapsed or refractory B-cell or T-cell ALL, including lymphoblastic lymphoma, after at least one line of chemotherapy * ELIGIBILITY CRITERIA - PHASE II (ARM D) - STEP 1: Age \>= 18 years * ELIGIBILITY CRITERIA - PHASE II (ARM D) - STEP 1: ECOG performance status 0-2 * ELIGIBILITY CRITERIA - PHASE II (ARM D) - STEP 1: Adequate liver function with AST/ALT less than 3 x upper limit of normal and total bilirubin less than 2 mg/dL within 10 days prior to first dose of study agent * ELIGIBILITY CRITERIA - PHASE II (ARM D) - STEP 1: Circulating WBC count must not be above 25 x 10\^9/L at the time of registration to step 1 * Patients with WBC count above 25 x 10\^9/L are eligible if they have started steroids or hydroxyurea per institutional guidelines * ELIGIBILITY CRITERIA - PHASE II (ARM D) - STEP 1: GFR of at least 40 mL/min within 7 days prior to first dose of study agent * ELIGIBILITY CRITERIA - PHASE II (ARM D) - STEP 1: All patients of childbearing potential must have a blood test or urine study with a minimum sensitivity 25 IU/L or equivalent units of HCG within 2 weeks prior to registration to rule out pregnancy. * A patient of childbearing potential is defined as anyone, regardless of sexual orientation or whether they have undergone tubal ligation, who meets the following criteria: 1) has achieved menarche at some point, 2) has not undergone a hysterectomy or bilateral oophorectomy; or 3) has not been naturally postmenopausal for at least 24 consecutive months (i.e., has had menses at any time in the preceding 24 consecutive months) * ELIGIBILITY CRITERIA - PHASE II (ARM D) - STEP 1: Patients must not expect to conceive or father children by using accepted and highly effective method(s) of contraception or by abstaining from sexual intercourse for the duration of their participation in the study and for 30 days after the last dose of venetoclax * Should a patient or partner of a patient become pregnant or suspect she is pregnant while participating in this study, the treating physician should be informed immediately * ELIGIBILITY CRITERIA - PHASE II (ARM D) - STEP 1: Patients may be enrolled with a prior allogeneic hematopoietic stem cell transplant (HSCT) but the transplant date must be at least 90 days before date of enrollment; patient must be off immunosuppression and without active GVHD prior to enrollment if previous HSCT. Low-dose steroids (10mg or less) are allowed Exclusion Criteria: * ELIGIBILITY CRITERIA - PHASE I (ARMS A, B, C) - STEP 1: Patients of childbearing potential must not be pregnant or breast-feeding due to risk of fetal harm by the chemotherapeutic agents prescribed in this protocol * ELIGIBILITY CRITERIA - PHASE I (ARMS A, B, C) - STEP 1: Patients with isolated testicular or central nervous system (CNS) relapsed disease are not eligible * ELIGIBILITY CRITERIA - PHASE I (ARMS A, B, C) - STEP 1: Patients must not have Burkitt's lymphoma/leukemia based on the World Health Organization (WHO) criteria * ELIGIBILITY CRITERIA - PHASE I (ARMS A, B, C) - STEP 1: Patients must not have active central nervous system (CNS) leukemia, as defined by unequivocal morphologic evidence of lymphoblasts in the cerebrospinal fluid (CSF) or the use of CNS-directed local treatment for active disease within the prior 28 days; prophylactic intrathecal chemotherapy is allowed; previously treated CNS disease with documented clearance of the CSF will be allowed * ELIGIBILITY CRITERIA - PHASE I (ARMS A, B, C) - STEP 1: Patients will not be enrolled if they received prior chemotherapy within 2 weeks before registration to step 1 with the following exceptions: to reduce the circulating lymphoblast count or palliation or for ALL maintenance (mercaptopurine, methotrexate, vincristine, thioguanine, and/or tyrosine kinase inhibitors) * ELIGIBILITY CRITERIA - PHASE I (ARMS A, B, C) - STEP 1: Patients cannot have poorly controlled chronic viral infections including hepatitis B, C, or human immunodeficiency virus (HIV); HIV positive patients are allowed on this study if they have a CD4 count \>= 400, and are on a stable antiviral regimen * ELIGIBILITY CRITERIA - PHASE I (ARMS A, B, C) - STEP 1: Patients with New York Heart Association (NYHA) class III or IV heart failure, uncontrolled angina, severe uncontrolled ventricular arrhythmias, or electrocardiographic evidence of acute ischemia may not be enrolled * ELIGIBILITY CRITERIA - PHASE I (ARMS A, B, C) - STEP 1: Patients with serious medical or psychiatric illness that in the opinion of the primary investigator is likely to interfere with study participation may not be enrolled * ELIGIBILITY CRITERIA - PHASE I (ARMS A, B, C) - STEP 1: Patients must not be taking any other experimental medications within 21 days prior to registration. Clinical trial medications that are Food and Drug Administration (FDA) approved will be allowed within 14 days prior to registration * ELIGIBILITY CRITERIA - PHASE I (ARMS A, B, C) - STEP 1: Patients should not have received the following within 7 days prior to the first dose of study drug: * Strong and moderate CYP3A inhibitors; * Strong and moderate CYP3A inducers * ELIGIBILITY CRITERIA - PHASE I (ARMS A, B, C) - STEP 1: Patients must not have grade 3 or higher peripheral neuropathy or history of grade 3 or higher peripheral neuropathy. Patients with familial demyelinating disease like Charcot-Marie-Tooth disease are also excluded * ELIGIBILITY CRITERIA - PHASE II (ARM D) - STEP 1: Patients with prior venetoclax treatment for ALL will be excluded * ELIGIBILITY CRITERIA - PHASE II (ARM D) - STEP 1: Patients must not be pregnant or breast-feeding due to risk of fetal harm by the chemotherapeutic agents prescribed in this protocol * ELIGIBILITY CRITERIA - PHASE II (ARM D) - STEP 1: No evidence of prior malignancy except adequately treated non-melanoma skin cancer, in situ cervical or breast carcinoma, or chemotherapy-surgically- or radiation-cured malignancy continuously disease free for \>= 2 years * ELIGIBILITY CRITERIA - PHASE II (ARM D) - STEP 1: Patients with isolated testicular or CNS relapsed disease are not eligible * ELIGIBILITY CRITERIA - PHASE II (ARM D) - STEP 1: Patients must not have Burkitt's lymphoma/leukemia based on the WHO criteria * ELIGIBILITY CRITERIA - PHASE II (ARM D) - STEP 1: Patients must not have active central nervous system (CNS) leukemia, as defined by unequivocal morphologic evidence of lymphoblasts in the cerebrospinal fluid (CSF) or the use of CNS-directed local treatment for active disease within the prior 28 days; prophylactic intrathecal chemotherapy is allowed; previously treated CNS disease with documented clearance of the CSF will be allowed and once cleared, prophylactic intrathecal chemotherapy can be continued * ELIGIBILITY CRITERIA - PHASE II (ARM D) - STEP 1: Patient will not be enrolled if they received prior chemotherapy within 2 weeks before enrollment with the following exceptions: to reduce the circulating lymphoblast count or palliation (i.e., steroids or hydroxyurea), for ALL maintenance (mercaptopurine, methotrexate, vincristine, thioguanine, and/or tyrosine kinase inhibitors) * ELIGIBILITY CRITERIA - PHASE II (ARM D) - STEP 1: Patients cannot have poorly controlled chronic viral infections including hepatitis B, C, or HIV; HIV positive patients with undetectable viral load are allowed * ELIGIBILITY CRITERIA - PHASE II (ARM D) - STEP 1: Patients with NYHA class III or IV heart failure, uncontrolled angina, severe uncontrolled ventricular arrhythmias, or electrocardiographic evidence of acute ischemia may not be enrolled * ELIGIBILITY CRITERIA - PHASE II (ARM D) - STEP 1: Patients with serious medical or psychiatric illness that in the opinion of the primary investigator is likely to interfere with study participation may not be enrolled * ELIGIBILITY CRITERIA - PHASE II (ARM D) - STEP 1: Patients must not be participating in any other clinical trial or taking any other experimental medications within 21 days prior to registration * ELIGIBILITY CRITERIA - PHASE II (ARM D) - STEP 1: Patients must not have received the following within 7 days prior to the first dose of study drug or while on study treatment: * Strong and moderate CYP3A inhibitors; * Strong and moderate CYP3A inducers * ELIGIBILITY CRITERIA - PHASE II (ARM D) - STEP 1: Patients must not have grade 3 or higher peripheral neuropathy or history of grade 3 peripheral neuropathy; patients with familial demyelinating diseases like Charcot-Marie-Tooth disease also excluded

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Recurrent adult lymphoblastic lymphoma are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

B-cell acute lymphoblastic leukemia Burkitt lymphoma lymphoblastic lymphoma Precursor B-Cell Lymphoblastic Leukemia-Lymphoma Precursor Cell Lymphoblastic Leukemia-Lymphoma Precursor T-Cell Lymphoblastic Leukemia-Lymphoma refractory precursor T-lymphoblastic lymphoma/leukemia T-cell acute lymphoblastic leukemia T-lymphoblastic lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Recurrent adult lymphoblastic lymphoma Recurrent B acute lymphoblastic leukemia Recurrent B lymphoblastic lymphoma Recurrent T acute lymphoblastic leukemia Recurrent T lymphoblastic lymphoma Refractory B acute lymphoblastic leukemia Refractory B lymphoblastic lymphoma Refractory T acute lymphoblastic leukemia Refractory T lymphoblastic lymphoma

Contacts and locations

Locations

  • Abbott-Northwestern Hospital

    Minneapolis, Minnesota, 55407, United States

  • Alaska Breast Care and Surgery LLC

    Anchorage, Alaska, 99508, United States

  • Alaska Oncology and Hematology LLC

    Anchorage, Alaska, 99508, United States

  • Alaska Women's Cancer Care

    Anchorage, Alaska, 99508, United States

  • Anchorage Associates in Radiation Medicine

    Anchorage, Alaska, 98508, United States

  • Anchorage Oncology Centre

    Anchorage, Alaska, 99508, United States

  • Anchorage Radiation Therapy Center

    Anchorage, Alaska, 99504, United States

  • BJC Outpatient Center at Sunset Hills

    Sunset Hills, Missouri, 63127, United States

  • Bay Area Hospital

    Coos Bay, Oregon, 97420, United States

  • CARTI Cancer Center

    Little Rock, Arkansas, 72205, United States

  • Cambridge Medical Center

    Cambridge, Minnesota, 55008, United States

  • Cancer Care Center of O'Fallon

    O'Fallon, Illinois, 62269, United States

  • Cancer Care Specialists of Illinois - Decatur

    Decatur, Illinois, 62526, United States

  • Cancer Center of Western Wisconsin

    New Richmond, Wisconsin, 54017, United States

  • Cancer Center-Metro Medical Center Bayamon

    Bayamón, 00959-5060, Puerto Rico

  • Central Care Cancer Center - Bolivar

    Bolivar, Missouri, 65613, United States

  • Central Care Cancer Center - Garden City

    Garden City, Kansas, 67846, United States

  • Central Care Cancer Center - Great Bend

    Great Bend, Kansas, 67530, United States

  • Centralia Oncology Clinic

    Centralia, Illinois, 62801, United States

  • Centro Comprensivo de Cancer de UPR

    San Juan, 00927, Puerto Rico

  • Clackamas Radiation Oncology Center

    Clackamas, Oregon, 97015, United States

  • Community Medical Center

    Toms River, New Jersey, 08755, United States

  • Cox Cancer Center Branson

    Branson, Missouri, 65616, United States

  • CoxHealth South Hospital

    Springfield, Missouri, 65807, United States

  • Crossroads Cancer Center

    Effingham, Illinois, 62401, United States

  • Dartmouth Hitchcock Medical Center/Dartmouth Cancer Center

    Lebanon, New Hampshire, 03756, United States

  • Decatur Memorial Hospital

    Decatur, Illinois, 62526, United States

  • Delbert Day Cancer Institute at PCRMC

    Rolla, Missouri, 65401, United States

  • Doctors Cancer Center

    Manati, 00674, Puerto Rico

  • Fairview Clinics and Surgery Center Maple Grove

    Maple Grove, Minnesota, 55369, United States

  • Fairview Lakes Medical Center

    Wyoming, Minnesota, 55092, United States

  • Fairview Northland Medical Center

    Princeton, Minnesota, 55371, United States

  • Fairview Ridges Hospital

    Burnsville, Minnesota, 55337, United States

  • Fairview Southdale Hospital

    Edina, Minnesota, 55435, United States

  • Freeman Health System

    Joplin, Missouri, 64804, United States

  • Good Samaritan Regional Health Center

    Mount Vernon, Illinois, 62864, United States

  • HSHS Saint Elizabeth's Hospital

    O'Fallon, Illinois, 62269, United States

  • Health Partners Inc

    Minneapolis, Minnesota, 55454, United States

  • Heartland Regional Medical Center

    Saint Joseph, Missouri, 64506, United States

  • Hennepin County Medical Center

    Minneapolis, Minnesota, 55415, United States

  • Houston Methodist Hospital

    Houston, Texas, 77030, United States

  • Illinois CancerCare - Washington

    Washington, Illinois, 61571, United States

  • Illinois CancerCare-Bloomington

    Bloomington, Illinois, 61704, United States

  • Illinois CancerCare-Canton

    Canton, Illinois, 61520, United States

  • Illinois CancerCare-Carthage

    Carthage, Illinois, 62321, United States

  • Illinois CancerCare-Dixon

    Dixon, Illinois, 61021, United States

  • Illinois CancerCare-Eureka

    Eureka, Illinois, 61530, United States

  • Illinois CancerCare-Galesburg

    Galesburg, Illinois, 61401, United States

  • Illinois CancerCare-Kewanee Clinic

    Kewanee, Illinois, 61443, United States

  • Illinois CancerCare-Macomb

    Macomb, Illinois, 61455, United States

  • Illinois CancerCare-Ottawa Clinic

    Ottawa, Illinois, 61350, United States

  • Illinois CancerCare-Pekin

    Pekin, Illinois, 61554, United States

  • Illinois CancerCare-Peoria

    Peoria, Illinois, 61615, United States

  • Illinois CancerCare-Peru

    Peru, Illinois, 61354, United States

  • Illinois CancerCare-Princeton

    Princeton, Illinois, 61356, United States

  • John H Stroger Jr Hospital of Cook County

    Chicago, Illinois, 60612, United States

  • Johns Hopkins University/Sidney Kimmel Cancer Center

    Baltimore, Maryland, 21287, United States

  • Kadlec Clinic Hematology and Oncology

    Kennewick, Washington, 99336, United States

  • Katmai Oncology Group

    Anchorage, Alaska, 99508, United States

  • Lake Regional Hospital

    Osage Beach, Missouri, 65065, United States

  • Lakeview Hospital

    Stillwater, Minnesota, 55082, United States

  • Loyola Center for Health at Burr Ridge

    Burr Ridge, Illinois, 60527, United States

  • Loyola Medicine Homer Glen

    Homer Glen, Illinois, 60491, United States

  • Loyola University Medical Center

    Maywood, Illinois, 60153, United States

  • MU Health Care Goldschmidt Cancer Center

    Jefferson City, Missouri, 65109, United States

  • Marjorie Weinberg Cancer Center at Loyola-Gottlieb

    Melrose Park, Illinois, 60160, United States

  • Marshfield Clinic-Minocqua Center

    Minocqua, Wisconsin, 54548, United States

  • Marshfield Medical Center - Weston

    Weston, Wisconsin, 54476, United States

  • Marshfield Medical Center-EC Cancer Center

    Eau Claire, Wisconsin, 54701, United States

  • Marshfield Medical Center-Marshfield

    Marshfield, Wisconsin, 54449, United States

  • Marshfield Medical Center-Rice Lake

    Rice Lake, Wisconsin, 54868, United States

  • Marshfield Medical Center-River Region at Stevens Point

    Stevens Point, Wisconsin, 54482, United States

  • Mayo Clinic Hospital in Arizona

    Phoenix, Arizona, 85054, United States

  • Mayo Clinic in Arizona

    Scottsdale, Arizona, 85259, United States

  • Mayo Clinic in Florida

    Jacksonville, Florida, 32224-9980, United States

  • Mayo Clinic in Rochester

    Rochester, Minnesota, 55905, United States

  • Medical College of Wisconsin

    Milwaukee, Wisconsin, 53226, United States

  • Memorial Hospital of Carbondale

    Carbondale, Illinois, 62902, United States

  • Memorial Medical Center

    Springfield, Illinois, 62781, United States

  • Memorial Sloan Kettering Cancer Center

    New York, New York, 10065, United States

  • Mercy Clinic-Rolla-Cancer and Hematology

    Rolla, Missouri, 65401, United States

  • Mercy Hospital

    Coon Rapids, Minnesota, 55433, United States

  • Mercy Hospital Fort Smith

    Fort Smith, Arkansas, 72903, United States

  • Mercy Hospital Joplin

    Joplin, Missouri, 64804, United States

  • Mercy Hospital Oklahoma City

    Oklahoma City, Oklahoma, 73120, United States

  • Mercy Hospital Saint Louis

    St Louis, Missouri, 63141, United States

  • Mercy Hospital South

    St Louis, Missouri, 63128, United States

  • Mercy Hospital Springfield

    Springfield, Missouri, 65804, United States

  • Mercy Hospital Washington

    Washington, Missouri, 63090, United States

  • Methodist Medical Center of Illinois

    Peoria, Illinois, 61636, United States

  • Minnesota Oncology - Burnsville

    Burnsville, Minnesota, 55337, United States

  • Minnesota Oncology Hematology PA-Maplewood

    Maplewood, Minnesota, 55109, United States

  • Minnesota Oncology Hematology PA-Woodbury

    Woodbury, Minnesota, 55125, United States

  • Missouri Baptist Medical Center

    St Louis, Missouri, 63131, United States

  • Missouri Baptist Sullivan Hospital

    Sullivan, Missouri, 63080, United States

  • Monmouth Medical Center

    Long Branch, New Jersey, 07740, United States

  • Monticello Cancer Center

    Monticello, Minnesota, 55362, United States

  • New Ulm Medical Center

    New Ulm, Minnesota, 56073, United States

  • North Memorial Medical Health Center

    Robbinsdale, Minnesota, 55422, United States

  • Northwestern University

    Chicago, Illinois, 60611, United States

  • OSF Saint Francis Medical Center

    Peoria, Illinois, 61637, United States

  • OSF Saint Francis Radiation Oncology at Pekin

    Pekin, Illinois, 61554, United States

  • OSF Saint Francis Radiation Oncology at Peoria Cancer Center

    Peoria, Illinois, 61615, United States

  • PROncology

    San Juan, 00927, Puerto Rico

  • Pacific Gynecology Specialists

    Seattle, Washington, 98104, United States

  • Park Nicollet Clinic - Saint Louis Park

    Saint Louis Park, Minnesota, 55416, United States

  • Parkland Health Center - Farmington

    Farmington, Missouri, 63640, United States

  • PeaceHealth Saint John Medical Center

    Longview, Washington, 98632, United States

  • PeaceHealth Saint Joseph Medical Center

    Bellingham, Washington, 98225, United States

  • PeaceHealth Southwest Medical Center

    Vancouver, Washington, 98664, United States

  • PeaceHealth United General Medical Center

    Sedro-Woolley, Washington, 98284, United States

  • Penn State Milton S Hershey Medical Center

    Hershey, Pennsylvania, 17033-0850, United States

  • Providence Alaska Medical Center

    Anchorage, Alaska, 99508, United States

  • Providence Cancer Institute Clackamas Clinic

    Clackamas, Oregon, 97015, United States

  • Providence Newberg Medical Center

    Newberg, Oregon, 97132, United States

  • Providence Portland Medical Center

    Portland, Oregon, 97213, United States

  • Providence Regional Cancer Partnership

    Everett, Washington, 98201, United States

  • Providence Regional Cancer System-Aberdeen

    Aberdeen, Washington, 98520, United States

  • Providence Regional Cancer System-Centralia

    Centralia, Washington, 98531, United States

  • Providence Regional Cancer System-Lacey

    Lacey, Washington, 98503, United States

  • Providence Regional Cancer System-Shelton

    Shelton, Washington, 98584, United States

  • Providence Regional Cancer System-Yelm

    Yelm, Washington, 98597, United States

  • Providence Saint Joseph Medical Center/Disney Family Cancer Center

    Burbank, California, 91505, United States

  • Providence Saint Mary Regional Cancer Center

    Walla Walla, Washington, 99362, United States

  • Providence Saint Vincent Medical Center

    Portland, Oregon, 97225, United States

  • Puerto Rico Hematology Oncology Group

    Bayamón, 00961, Puerto Rico

  • Regions Hospital

    Saint Paul, Minnesota, 55101, United States

  • Rice Memorial Hospital

    Willmar, Minnesota, 56201, United States

  • Ridgeview Medical Center

    Waconia, Minnesota, 55387, United States

  • Rutgers Cancer Institute of New Jersey

    New Brunswick, New Jersey, 08903, United States

  • SIH Cancer Institute

    Carterville, Illinois, 62918, United States

  • Saint Anthony's Health

    Alton, Illinois, 62002, United States

  • Saint Charles Health System

    Bend, Oregon, 97701, United States

  • Saint Charles Health System-Redmond

    Redmond, Oregon, 97756, United States

  • Saint Francis Cancer Center

    Greenville, South Carolina, 29607, United States

  • Saint Francis Hospital

    Greenville, South Carolina, 29601, United States

  • Saint Francis Medical Center

    Cape Girardeau, Missouri, 63703, United States

  • Saint Francis Regional Medical Center

    Shakopee, Minnesota, 55379, United States

  • Saint John's Hospital - Healtheast

    Maplewood, Minnesota, 55109, United States

  • Saint Louis Cancer and Breast Institute-Ballwin

    Ballwin, Missouri, 63011, United States

  • Saint Louis Cancer and Breast Institute-South City

    St Louis, Missouri, 63109, United States

  • Saint Luke's Cancer Institute - Boise

    Boise, Idaho, 83712, United States

  • Saint Luke's Cancer Institute - Fruitland

    Fruitland, Idaho, 83619, United States

  • Saint Luke's Cancer Institute - Meridian

    Meridian, Idaho, 83642, United States

  • Saint Luke's Cancer Institute - Nampa

    Nampa, Idaho, 83686, United States

  • Saint Luke's Cancer Institute - Twin Falls

    Twin Falls, Idaho, 83301, United States

  • Saint Mary's Hospital

    Centralia, Illinois, 62801, United States

  • Saint Patrick Hospital - Community Hospital

    Missoula, Montana, 59802, United States

  • Sainte Genevieve County Memorial Hospital

    Sainte Genevieve, Missouri, 63670, United States

  • San Juan City Hospital

    San Juan, 00936, Puerto Rico

  • San Juan Community Oncology Group

    San Juan, 00917, Puerto Rico

  • Smilow Cancer Center/Yale-New Haven Hospital

    New Haven, Connecticut, 06510, United States

  • Smilow Cancer Hospital Care Center at Saint Francis

    Hartford, Connecticut, 06105, United States

  • Southeast Cancer Center

    Cape Girardeau, Missouri, 63703, United States

  • Southern Illinois University School of Medicine

    Springfield, Illinois, 62702, United States

  • Springfield Clinic

    Springfield, Illinois, 62702, United States

  • Swedish Cancer Institute-Edmonds

    Edmonds, Washington, 98026, United States

  • Swedish Cancer Institute-Issaquah

    Issaquah, Washington, 98029, United States

  • Swedish Medical Center-Ballard Campus

    Seattle, Washington, 98107, United States

  • Swedish Medical Center-Cherry Hill

    Seattle, Washington, 98122-5711, United States

  • Swedish Medical Center-First Hill

    Seattle, Washington, 98122, United States

  • Thomas Jefferson University Hospital

    Philadelphia, Pennsylvania, 19107, United States

  • United Hospital

    Saint Paul, Minnesota, 55102, United States

  • Unity Hospital

    Fridley, Minnesota, 55432, United States

  • University of Florida Health Science Center - Jacksonville

    Jacksonville, Florida, 32209, United States

  • University of New Mexico Cancer Center

    Albuquerque, New Mexico, 87106, United States

  • University of Pennsylvania/Abramson Cancer Center

    Philadelphia, Pennsylvania, 19104, United States

  • Valley Radiation Oncology

    Peru, Illinois, 61354, United States

  • Western Illinois Cancer Treatment Center

    Galesburg, Illinois, 61401, United States

  • Yale University

    New Haven, Connecticut, 06520, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.